Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Hyoung Jin Kang et al.|The Lancet Oncology|2019Cited by 341
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With OsteosarcomaSharon A. Savage, Michael Dean, Meredith Yeager et al.|JAMA Oncology|2020Cited by 251